DK1373202T3 - Fremstilling af ikke-krystallinsk atorvastatincalcium - Google Patents
Fremstilling af ikke-krystallinsk atorvastatincalciumInfo
- Publication number
- DK1373202T3 DK1373202T3 DK02734878T DK02734878T DK1373202T3 DK 1373202 T3 DK1373202 T3 DK 1373202T3 DK 02734878 T DK02734878 T DK 02734878T DK 02734878 T DK02734878 T DK 02734878T DK 1373202 T3 DK1373202 T3 DK 1373202T3
- Authority
- DK
- Denmark
- Prior art keywords
- atorvastatin
- crystalline
- preparation
- salt
- atorvastatin calcium
- Prior art date
Links
- OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 title 1
- 229960001770 atorvastatin calcium Drugs 0.000 title 1
- XUKUURHRXDUEBC-KAYWLYCHSA-N Atorvastatin Chemical class C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@@H](O)C[C@@H](O)CC(O)=O)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 XUKUURHRXDUEBC-KAYWLYCHSA-N 0.000 abstract 3
- OUCSEDFVYPBLLF-KAYWLYCHSA-N 5-(4-fluorophenyl)-1-[2-[(2r,4r)-4-hydroxy-6-oxooxan-2-yl]ethyl]-n,4-diphenyl-2-propan-2-ylpyrrole-3-carboxamide Chemical compound C=1C=CC=CC=1C1=C(C=2C=CC(F)=CC=2)N(CC[C@H]2OC(=O)C[C@H](O)C2)C(C(C)C)=C1C(=O)NC1=CC=CC=C1 OUCSEDFVYPBLLF-KAYWLYCHSA-N 0.000 abstract 2
- 125000006239 protecting group Chemical group 0.000 abstract 2
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 159000000007 calcium salts Chemical class 0.000 abstract 1
- 125000006244 carboxylic acid protecting group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Obesity (AREA)
- Pyrrole Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SI200100010A SI20814A (sl) | 2001-01-23 | 2001-01-23 | Priprava amorfnega atorvastatina |
| PCT/IB2002/000161 WO2002059087A1 (en) | 2001-01-23 | 2002-01-22 | Preparation of non-crystalline atorvastatin calcium |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1373202T3 true DK1373202T3 (da) | 2005-05-17 |
Family
ID=20432812
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK02734878T DK1373202T3 (da) | 2001-01-23 | 2002-01-22 | Fremstilling af ikke-krystallinsk atorvastatincalcium |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6750353B2 (https=) |
| EP (1) | EP1373202B1 (https=) |
| JP (1) | JP4336106B2 (https=) |
| KR (1) | KR100882066B1 (https=) |
| CN (1) | CN1260213C (https=) |
| AT (1) | ATE294159T1 (https=) |
| AU (1) | AU2002219455B2 (https=) |
| BG (1) | BG108017A (https=) |
| BR (1) | BR0206637A (https=) |
| CA (1) | CA2435954C (https=) |
| CZ (1) | CZ20031988A3 (https=) |
| DE (1) | DE60203894T2 (https=) |
| DK (1) | DK1373202T3 (https=) |
| EE (1) | EE05270B1 (https=) |
| ES (1) | ES2240748T3 (https=) |
| HR (1) | HRP20030575B1 (https=) |
| HU (1) | HU227535B1 (https=) |
| IL (2) | IL157068A0 (https=) |
| MX (1) | MXPA03006548A (https=) |
| PL (1) | PL209428B1 (https=) |
| RS (1) | RS51010B (https=) |
| RU (1) | RU2324679C2 (https=) |
| SI (2) | SI20814A (https=) |
| SK (1) | SK286593B6 (https=) |
| UA (1) | UA73829C2 (https=) |
| WO (1) | WO2002059087A1 (https=) |
| ZA (1) | ZA200305307B (https=) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7411075B1 (en) | 2000-11-16 | 2008-08-12 | Teva Pharmaceutical Industries Ltd. | Polymorphic form of atorvastatin calcium |
| IL156055A0 (en) | 2000-11-30 | 2003-12-23 | Teva Pharma | Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms |
| US7501450B2 (en) | 2000-11-30 | 2009-03-10 | Teva Pharaceutical Industries Ltd. | Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms |
| CA2622477A1 (en) | 2000-12-27 | 2002-07-04 | Teva Pharmaceutical Industries Ltd. | Crystalline forms of atorvastatin |
| WO2002068335A2 (en) * | 2001-02-27 | 2002-09-06 | Council Of Scientific And Industrial Research | Essential oil composition for potable water disinfection |
| SK16002003A3 (sk) | 2001-06-29 | 2004-12-01 | Warner-Lambert Company Llc | Kryštalické formy vápenatej soli (2:1) [R-(R*,R*)]-2-(4-fluóro- fenyl)-beta,delta-dihydroxy-5-(1-metyletyl)-3-fenyl-4- [(fenylamino)karbonyl]-1H-pyrrol-1-heptánovej kyseliny (atorvastatín) |
| WO2005033078A1 (en) * | 2003-10-07 | 2005-04-14 | Biocon Limited | Process for the production of atorvastatin calcium |
| HU227124B1 (en) * | 2001-09-14 | 2010-07-28 | Egis Gyogyszergyar Nyilvanosan | Polymorphs of 1-pyrrole derivative, intermediate for the preparation of atorvastatin |
| CN100379723C (zh) | 2002-02-19 | 2008-04-09 | 特瓦制药工业有限公司 | 阿托伐他汀半钙脱溶剂的方法和基本上不含有机溶剂的阿托伐他汀半钙 |
| ITMI20020907A1 (it) * | 2002-04-29 | 2003-10-29 | Chemi Spa | Processo di preparazione della forma amorfa del sale di calcio della atorvastatina |
| CA2385529A1 (en) * | 2002-05-21 | 2003-11-21 | Bernard Charles Sherman | Stable dosage forms comprising atorvastatin calcium |
| CA2520740C (en) * | 2003-04-11 | 2012-06-05 | Lek Pharmaceuticals D.D. | Process for the preparation of amorphous calcium salt of atorvastatin |
| US7790197B2 (en) | 2003-06-09 | 2010-09-07 | Warner-Lambert Company Llc | Pharmaceutical compositions of atorvastatin |
| US20050271717A1 (en) | 2003-06-12 | 2005-12-08 | Alfred Berchielli | Pharmaceutical compositions of atorvastatin |
| US7655692B2 (en) | 2003-06-12 | 2010-02-02 | Pfizer Inc. | Process for forming amorphous atorvastatin |
| EP1648903A2 (en) | 2003-07-02 | 2006-04-26 | Egis Gyogyszergyar Rt. | Process for the preparation of amorphous form of a platelet aggregation inhibitor drug |
| AU2003247327A1 (en) * | 2003-07-15 | 2005-01-28 | Eos Eczacibasi Ozgun Kimyasal Urunler Sanyi Ve Ticaret A.S. | Process for the preparation of amortphous atorvastatin calcium without interconversion of any crystalline form |
| JP2007517028A (ja) * | 2003-12-29 | 2007-06-28 | レツク・フアーマシユーテイカルズ・デー・デー | 非晶質の（４ｒ−シス）−６−［２−［３−フェニル−４−（フェニルカルバモイル）−２−（４−フルオロフェニル）−５−（１−メチルエチル）−ピロール−１−イル］−エチル］−２，２−ジメチル−［１，３］−ジオキサン−４−イル−酢酸を調製する方法 |
| ATE545629T1 (de) | 2004-03-17 | 2012-03-15 | Ranbaxy Lab Ltd | Verfahren zur herstellung von atorvastatin- calcium in amorpher form |
| US7875731B2 (en) | 2004-05-05 | 2011-01-25 | Pfizer Inc. | Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β, δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)Carbonyl]-1H-pyrrole-1-heptanoic acid |
| US8044086B2 (en) * | 2004-07-16 | 2011-10-25 | Lek Pharmaceuticals D.D. | Oxidative degradation products of atorvastatin calcium |
| CA2701710C (en) | 2004-07-20 | 2013-08-27 | Warner-Lambert Company Llc | Novel forms of [r-(r*,r*)]-2-(4-fluorophenyl)-.beta.,.delta.-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| WO2006011155A1 (en) * | 2004-07-26 | 2006-02-02 | Apollo International Limited | One pot process for amorphous atorvastain calcium |
| US7645888B2 (en) | 2004-08-27 | 2010-01-12 | Biocon Limited | Process for the production of amorphous atorvastatin calcium |
| AU2005298383A1 (en) | 2004-10-28 | 2006-05-04 | Warner-Lambert Company Llc | Process for forming amorphous atorvastatin |
| ES2270722B1 (es) * | 2005-09-15 | 2008-03-01 | Ercros Industrial, S.A. | Procedimiento para la obtencion de atorvastatina calcica amorfa. |
| US20090216029A1 (en) * | 2005-09-16 | 2009-08-27 | Yatendra Kumar | Process for the production of atorvastatin calcium in amorphous form |
| CA2547216A1 (en) | 2005-09-21 | 2007-03-21 | Renuka D. Reddy | Process for annealing amorphous atorvastatin |
| ATE466840T1 (de) | 2005-11-21 | 2010-05-15 | Warner Lambert Co | Neue formen von är-(r*,r*)ü-2-(4-fluorphenyl)-b,d-dihydroxy-5-( -methylethyl)-3-phenyl-4- ä(phenylamino)carbonylü-1h-pyrrol-1-heptansäure magnesium |
| EP1810667A1 (en) | 2006-01-20 | 2007-07-25 | KRKA, tovarna zdravil, d.d., Novo mesto | Pharmaceutical composition comprising amorphous atorvastatin |
| EP1979313A1 (en) * | 2006-01-31 | 2008-10-15 | Jubilant Organosys Limited | Process for the preparation of amorphous atorvastatin calcium salt |
| CN100406438C (zh) * | 2006-06-30 | 2008-07-30 | 浙江新东港药业股份有限公司 | 一种无定型阿伐他汀钙的制备方法 |
| US20100113802A1 (en) * | 2006-11-02 | 2010-05-06 | Cadila Pharmaceuticals Limited | Process for preparing amorphous atorvastatin hemi calcium salt and its itermediate |
| KR100833439B1 (ko) * | 2007-01-02 | 2008-05-29 | 씨제이제일제당 (주) | 비결정형 아토르바스타틴 칼슘의 개선된 제조방법 |
| WO2009052246A1 (en) | 2007-10-17 | 2009-04-23 | Ovokaitys, Todd, F. | Process for the modification of the solid state of a compound and co-amorphous compositions produced with same |
| WO2009139730A1 (en) * | 2008-05-13 | 2009-11-19 | Ulkar Kimya San. Ve Tic. A.S. | Preparation of novel non-crystalline forms of atorvastatin calcium |
| KR101050722B1 (ko) | 2008-12-02 | 2011-07-21 | 대웅바이오 주식회사 | 무정형 아토르바스타틴 칼슘염의 제조방법 |
| US8115015B2 (en) * | 2009-01-26 | 2012-02-14 | Cadila Healthcare Limited | Process for the preparation of amorphous atorvastatin calcium |
| US20130041162A1 (en) * | 2010-04-19 | 2013-02-14 | Dsm Sinochem Pharmaceuticals Netherlands B.V. | Production of atorvastatin low in ether impurities |
| HUP1000299A2 (hu) | 2010-06-08 | 2012-02-28 | Nanoform Cardiovascular Therapeutics Ltd | Nanostrukturált Atorvastatint, gyógyszerészetileg elfogadott sóit és kokristályait tartalmazó készítmény és eljárás elõállításukra |
| CN102796036B (zh) * | 2012-09-12 | 2014-06-04 | 江苏阿尔法药业有限公司 | 一种阿托伐他汀钙的制备方法 |
| US10202598B2 (en) | 2014-05-30 | 2019-02-12 | Todd Frank Ovokaitys | Methods and systems for generation, use, and delivery of activated stem cells |
| US10384985B2 (en) | 2014-06-06 | 2019-08-20 | B.K. Consultants, Inc. | Methods and compositions for increasing the yield of, and beneficial chemical composition of, certain plants |
| US10040728B2 (en) | 2014-06-06 | 2018-08-07 | Todd Frank Ovokaitys | Methods and compositions for increasing the bioactivity of nutrients |
| CN113321607A (zh) * | 2020-02-28 | 2021-08-31 | 北京福元医药股份有限公司沧州分公司 | 一种阿托伐他汀钙中间体的纯化方法 |
| WO2022126109A1 (en) | 2020-12-08 | 2022-06-16 | Ovokaitys Todd Frank | Methods and systems for increased production of stem cells |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4681893A (en) | 1986-05-30 | 1987-07-21 | Warner-Lambert Company | Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis |
| US5216174A (en) | 1988-02-22 | 1993-06-01 | Warner-Lambert Co. | Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5245047A (en) | 1988-02-22 | 1993-09-14 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5003080A (en) | 1988-02-22 | 1991-03-26 | Warner-Lambert Company | Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis |
| US5149837A (en) | 1988-02-22 | 1992-09-22 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5097045A (en) | 1989-02-01 | 1992-03-17 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5124482A (en) | 1988-02-22 | 1992-06-23 | Warner-Lambert Company | Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis |
| FI94339C (fi) | 1989-07-21 | 1995-08-25 | Warner Lambert Co | Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi |
| US5103024A (en) | 1990-10-17 | 1992-04-07 | Warner-Lambert Company | Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate |
| US5155251A (en) | 1991-10-11 | 1992-10-13 | Warner-Lambert Company | Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate |
| US5298627A (en) | 1993-03-03 | 1994-03-29 | Warner-Lambert Company | Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis |
| US5798375A (en) * | 1995-07-03 | 1998-08-25 | Sankyo Company, Limited | Treatment of arteriosclerosis and xanthoma |
| HRP960312B1 (en) * | 1995-07-17 | 2001-10-31 | Warner Lambert Co | NOVEL PROCESS FOR THE PRODUCTION OF AMORPHOUS /R-(R*, R*)/-2-(4-FLUOROPHENYL)-"beta", "delta"-DIHYDROXY-5-PHENYL-4-/(PHENYLAMINO)CARBONYL/-1H-PYRROLE -1-HEPTANOIC ACID CALCIUM SALT (2 : 1) |
| HRP960313B1 (en) | 1995-07-17 | 2002-08-31 | Warner Lambert Co | Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1) |
| KR100389518B1 (ko) * | 1995-07-17 | 2003-11-15 | 워너-램버트 캄파니 엘엘씨 | 결정질[r-(r*,r*)]-2-(4-플루오로페닐)-베타,델타-디히드록시-5-(1-메틸에틸)-3-페닐-4-[(페닐아미노)카르보닐]-1h-피롤-1-헵탄산헤미칼슘염(아토르바스타틴) |
| US6087511A (en) * | 1996-07-16 | 2000-07-11 | Warner-Lambert Company | Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1) |
| IN191236B (https=) * | 1999-05-25 | 2003-10-11 | Ranbaxy Lab Ltd |
-
2001
- 2001-01-23 SI SI200100010A patent/SI20814A/sl not_active IP Right Cessation
-
2002
- 2002-01-22 JP JP2002559389A patent/JP4336106B2/ja not_active Expired - Fee Related
- 2002-01-22 WO PCT/IB2002/000161 patent/WO2002059087A1/en not_active Ceased
- 2002-01-22 CN CNB028039688A patent/CN1260213C/zh not_active Expired - Fee Related
- 2002-01-22 UA UA2003076436A patent/UA73829C2/uk unknown
- 2002-01-22 RU RU2003124962/04A patent/RU2324679C2/ru not_active IP Right Cessation
- 2002-01-22 EE EEP200300333A patent/EE05270B1/xx not_active IP Right Cessation
- 2002-01-22 MX MXPA03006548A patent/MXPA03006548A/es active IP Right Grant
- 2002-01-22 CZ CZ20031988A patent/CZ20031988A3/cs unknown
- 2002-01-22 DE DE60203894T patent/DE60203894T2/de not_active Expired - Lifetime
- 2002-01-22 AU AU2002219455A patent/AU2002219455B2/en not_active Ceased
- 2002-01-22 SI SI200230156T patent/SI1373202T1/sl unknown
- 2002-01-22 HU HU0302797A patent/HU227535B1/hu not_active IP Right Cessation
- 2002-01-22 HR HR20030575A patent/HRP20030575B1/xx not_active IP Right Cessation
- 2002-01-22 DK DK02734878T patent/DK1373202T3/da active
- 2002-01-22 CA CA002435954A patent/CA2435954C/en not_active Expired - Fee Related
- 2002-01-22 EP EP02734878A patent/EP1373202B1/en not_active Expired - Lifetime
- 2002-01-22 AT AT02734878T patent/ATE294159T1/de active
- 2002-01-22 ES ES02734878T patent/ES2240748T3/es not_active Expired - Lifetime
- 2002-01-22 SK SK908-2003A patent/SK286593B6/sk not_active IP Right Cessation
- 2002-01-22 IL IL15706802A patent/IL157068A0/xx unknown
- 2002-01-22 KR KR1020037009509A patent/KR100882066B1/ko not_active Expired - Fee Related
- 2002-01-22 RS YUP-568/03A patent/RS51010B/sr unknown
- 2002-01-22 BR BR0206637-8A patent/BR0206637A/pt not_active IP Right Cessation
- 2002-01-22 PL PL361763A patent/PL209428B1/pl unknown
- 2002-12-18 US US10/323,444 patent/US6750353B2/en not_active Expired - Fee Related
-
2003
- 2003-07-09 ZA ZA200305307A patent/ZA200305307B/xx unknown
- 2003-07-22 BG BG108017A patent/BG108017A/bg unknown
- 2003-07-23 IL IL157068A patent/IL157068A/en not_active IP Right Cessation
- 2003-10-03 US US10/677,344 patent/US7074940B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK1373202T3 (da) | Fremstilling af ikke-krystallinsk atorvastatincalcium | |
| WO2001096334A3 (en) | Heteroarylalkanoic acids as integrin receptor antagonists | |
| AUPR213700A0 (en) | Antiviral agents | |
| CY1108559T1 (el) | Αλατα βαλσαρτανης | |
| PT1379520E (pt) | Antagonistas (nao-aril)-heterociclicos n-substituidos de nmda/nr2b | |
| EE05103B1 (et) | Famatseutilised kompositsioonid, mis sisaldavad asetidiini derivaate, asetidiini derivaadid ja nende valmistamise meetodid | |
| DK0894084T3 (da) | Kanelsyrederivater og deres anvendelse som integrinantagonister | |
| ZA9711607B (en) | Novel cyclosporin derivatives, their preparation and the pharmaceutical compositions which contain them. | |
| DK0734383T3 (da) | Cykliske amidderivater som neurokinin-A-antagonister | |
| WO2001096307A3 (en) | Cycloalkyl alkanoic acids as integrin receptor antagonists | |
| WO2004096823A3 (en) | Novel ketolide derivatives | |
| ES2307511T3 (es) | Derivados de eritromicina c-2 modificados. | |
| WO2001064645A3 (en) | Derivatives of quinoline as alpha-2 antagonists | |
| DE69709493D1 (de) | Substituierte Indazolderivate | |
| WO2001027110A3 (de) | Am sechsring substituierte, bicyclische imidazo-3-yl-aminderivate | |
| WO2001081316A3 (en) | Substituted phenyl farnesyltransferase inhibitors | |
| CA2393757A1 (en) | Cycloamine ccr5 receptor antagonists | |
| WO2004111008A3 (en) | Use of a compound of formula i for making a pharmaceutical composition | |
| DE69734678D1 (de) | 6-0-substitutierte eryththromycin-verbindungen und verfahrenen zu ihrer herstellung | |
| ATE266029T1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| MX9207204A (es) | Preparado farmaceutico y procedimiento para su fabricacion. | |
| DE69927997D1 (de) | Neuartige pyrimidin-derivate und verfahren zu ihrer herstellung | |
| AP2002002679A0 (en) | Novel polymorph V of torasemide. | |
| WO2004048381A3 (en) | Pyrazoloazepine compounds as pharmaceutical agents | |
| WO2005051349A3 (en) | Pharmaceutical compositions of mirtazapine |